HHS proposes allowing some drug importation, but impact would be limited
Nevertheless, the proposed policy could take Martin Shkreli-like practices "out of the ballgame," expert says.
Morning Read: Valeant settles Salix investigation, Alphabet defends Verily
Plus, Boston Scientific to restructure, Practice Fusion agrees to settle FTC charges and a Martin Shkreli musical is in the works.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Morning Read: BioMarin pulls plug on $680M Duchenne drug, Valeant’s Pearson cashes in
Plus, health insurance startup Oscar to build concierge clinic in Arizona, AIDS Healthcare Foundation wants the FDA and Congress to investigate Gilead and eHealth hires its new CEO from Playboy.
Morning Read: Valeant says at least we’re not Turing, questions about BMJ study on medical errors
Also, Chimerix reports another failed Phase 3 trial of brincidofovir, population health IT tools may become "irrelevant" and Republican healthcare policy wonks distance themselves from Trump.
Morning Read: Warren Buffett calls Valeant ‘enormously flawed,’ Hollywood discovers science star
Also, Spring Bank Pharmaceuticals scales back its IPO, troubled health insurer Moda raises $165 million and bill would allow automatic Medicare reimbursement for newly approved breakthrough medical devices.
Morning Read: Outgoing Valeant CEO to say company raised prices too much, UK doctors strike
Plus, UCSF receives $185 million gift for neurosciences institute and New York doc charged with writing 300,000 illegal painkiller prescriptions.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Valeant has a new CEO whose strength is ‘fostering an ethical culture’
Valeant Pharmaceuticals just poached Perrigo CEO Joseph Papa to be its new chief executive. He'll replace the somewhat reviled current CEO, Michael Pearson, in early May.
Morning Read: Pharma changes afoot as Valeant courts a new CEO and Novartis U.S. head exits
Also, Dr. Francis Collins offers action plan on how it will fix safety issues for National Institutes of Health Clinical Center research hospital, and synthetic cartilage implant developer Cartiva clears one hurdle in its path to FDA clearance.
Cures Within Reach: “Creating the opposite of Valeant”
The organization's all about generic drugs - but unlike, say, Martin Shkreli, Bloom's big idea is to repurpose existing drugs and lessen the overall costs of healthcare.
Valeant looking for new CEO as Pearson steps down – desperation calls for change?
Today it was announced that Valeant CEO Mike Pearson is officially walking away from his position with the pharmaceutical company, though he will stay on board until a replacement is established.
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Morning Read: Valeant’s Michael Pearson is back at work, where is all the HIMSS16 coverage?
Also, CEO succession plans at GSK, Sanofi's plans to buy orphan drug companies, doctors healthcare social media habits and long looks at Bernie Sanders and Donald Trump's health plans.
Morning Read: Valeant loses $6 billion in value, the digital health drumbeat hits Harvard
Plus, a new Parkinson's project in Britain, a $70M fund-raise for Alzheimer's drugs, Tenet outlines its financials, and more HIMSS 2016 advice.
A gutsy move: Valeant runs Super Bowl commercial for Xifaxan
Valeant Pharmaceuticals had another Super Bowl commercial this year: It featured its anthropomorphized intestine to advertise IBS drug Xifaxan.
Martin Shkreli has been subpoenaed by congressional committee that investigates drug prices
Along with Turing Pharmaceuticals, of which Martin Shkreli was formerly CEO, Valeant Pharmaceuticals will be investigated by Congress on January 26, Bloomberg reports.
Morning Read: Valeant CEO remains in hospital with pneumonia
Also, new details about consumer attitudes toward healthcare and a Japanese ad agency invests in health trackers.